Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TXG
stocks logo

TXG

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
139.41M
-8.95%
--
--
143.60M
-5.31%
--
--
155.21M
-5.94%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for 10x Genomics, Inc. (TXG) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 15.60%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+15.60%
In Past 3 Month
Wall Street analysts forecast TXG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXG is 13.00 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast TXG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXG is 13.00 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 15.560
sliders
Low
9.00
Averages
13.00
High
18.00
Current: 15.560
sliders
Low
9.00
Averages
13.00
High
18.00
Piper Sandler
Neutral
maintain
$15 -> $19
2025-11-11
Reason
Piper Sandler
Price Target
$15 -> $19
2025-11-11
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on 10x Genomics to $19 from $15 and keeps a Neutral rating on the shares. The firm cites the company's quarterly results for the price target change.
Canaccord
Buy
maintain
$16 -> $19
2025-11-07
Reason
Canaccord
Price Target
$16 -> $19
2025-11-07
maintain
Buy
Reason
Canaccord raised the firm's price target on 10x Genomics to $19 from $16 and keeps a Buy rating on the shares. The firm said TXG remains one their top picks in Tools after a solid 3Q25, as they are optimistic that the company can reaccelerate growth in the relative near term.
JPMorgan
Neutral
maintain
$13 -> $15
2025-11-07
Reason
JPMorgan
Price Target
$13 -> $15
2025-11-07
maintain
Neutral
Reason
JPMorgan raised the firm's price target on 10x Genomics to $15 from $13 and keeps a Neutral rating on the shares following the Q3 report.
UBS
Neutral
maintain
$13 -> $14
2025-11-07
Reason
UBS
Price Target
$13 -> $14
2025-11-07
maintain
Neutral
Reason
UBS raised the firm's price target on 10x Genomics to $14 from $13 and keeps a Neutral rating on the shares. While 10x Genomics posted a quarterly beat and guidance above expectations, the muted demand environment is persisting, the analyst tells investors in a research note.
Barclays
Luke Sergott
Overweight
maintain
$15 -> $17
2025-11-07
Reason
Barclays
Luke Sergott
Price Target
$15 -> $17
2025-11-07
maintain
Overweight
Reason
Barclays analyst Luke Sergott raised the firm's price target on 10x Genomics to $17 from $15 and keeps an Overweight rating on the shares. The firm says the company's new product launches across single cell and spatial put the portfolio in a better spot for when demand does come back.
Piper Sandler
David Westenberg
Neutral
initiated
$15
2025-09-11
Reason
Piper Sandler
David Westenberg
Price Target
$15
2025-09-11
initiated
Neutral
Reason
Piper Sandler analyst David Westenberg initiated coverage of 10x Genomics with a Neutral rating and $15 price target. The firm believes 10x has the best offering in single cell with the largest install base and a technological lead versus competitors. However, Piper recommends waiting for the company to navigate the current macro environment before buying the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for 10X Genomics Inc (TXG.O) is -8.62, compared to its 5-year average forward P/E of -106.77. For a more detailed relative valuation and DCF analysis to assess 10X Genomics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-106.77
Current PE
-8.62
Overvalued PE
38.47
Undervalued PE
-252.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-556.22
Current EV/EBITDA
-7.40
Overvalued EV/EBITDA
1261.92
Undervalued EV/EBITDA
-2374.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
13.86
Current PS
2.13
Overvalued PS
26.03
Undervalued PS
1.69
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 211.59% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 211.59% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

TXG News & Events

Events Timeline

(ET)
2025-11-06
16:27:42
10x Genomics announces Q3 earnings per share of 22 cents, compared to a loss of 30 cents in the same period last year.
select
2025-10-20 (ET)
2025-10-20
12:35:59
10x Genomics Forms Alliance with Anthropic
select
2025-09-09 (ET)
2025-09-09
09:10:45
10x Genomics and Cliseq Ltd. to Explore Single Cell Applications
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-12PRnewswire
10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025

  • Event Announcement: 10x Genomics will participate in a fireside chat at the Wolfe Research Healthcare Conference on November 18, 2025, at 11:20 a.m. Eastern Time, with a live webcast available on their website.

  • Company Overview: 10x Genomics is a life science technology company focused on single cell and spatial biology, providing integrated research solutions that aid in understanding complex biological systems and advancing human health.

[object Object]
Preview
9.5
11-11NASDAQ.COM
Is It Time to Buy, Hold, or Sell TEM Stock After Q3 Earnings Report?

  • Tempus AI Inc. Q3 2025 Results: Tempus reported a narrower loss of $0.11 per share and an 84.7% increase in revenue to $252.9 million, marking its first positive adjusted EBITDA after a decade of efforts.

  • Competitive Landscape: Rivals 10x Genomics and Doximity also reported strong earnings, with 10x Genomics posting a loss of $0.22 per share and revenue of $149 million, while Doximity achieved adjusted EPS of $0.45 and revenues of $168.5 million.

  • Growth and Innovation: Tempus is expanding its offerings with new products like the xM liquid biopsy assay and plans for a whole-genome sequencing test, alongside strategic partnerships and acquisitions to enhance its data and AI capabilities.

  • Market Position and Future Outlook: Despite a high price-to-sales ratio, Tempus is positioned for growth with expected revenue increases of 80% in Q4 2025 and ongoing regulatory efforts to improve reimbursement rates, suggesting a strong long-term value potential.

[object Object]
Preview
6.0
11-08NASDAQ.COM
Barclays Upholds Overweight Rating for 10x Genomics (TXG)

  • Analyst Coverage: Barclays has maintained an Overweight recommendation for 10x Genomics (NasdaqGS:TXG) as of November 7, 2025, with an average one-year price target of $15.08/share, indicating a potential 1.11% downside from its latest closing price.

  • Revenue and EPS Projections: The projected annual revenue for 10x Genomics is $878 million, reflecting a 36.78% increase, while the projected annual non-GAAP EPS is -0.58.

  • Fund Sentiment: There has been a notable increase in institutional ownership of 10x Genomics, with 602 funds reporting positions, a 13.80% increase from the previous quarter, and total shares owned rising by 6.89% to 147,568K shares.

  • Shareholder Activity: Significant increases in shareholdings were reported by ARK Investment Management, ARKK - ARK Innovation ETF, and Nikko Asset Management Americas, while Sumitomo Mitsui Trust Holdings decreased its holdings. Aqr Capital Management saw a substantial increase of 231.56% in its portfolio allocation.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is 10X Genomics Inc (TXG) stock price today?

The current price of TXG is 15.56 USD — it has decreased -0.89 % in the last trading day.

arrow icon

What is 10X Genomics Inc (TXG)'s business?

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

arrow icon

What is the price predicton of TXG Stock?

Wall Street analysts forecast TXG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXG is 13.00 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is 10X Genomics Inc (TXG)'s revenue for the last quarter?

10X Genomics Inc revenue for the last quarter amounts to 154.88M USD, increased 9.84 % YoY.

arrow icon

What is 10X Genomics Inc (TXG)'s earnings per share (EPS) for the last quarter?

10X Genomics Inc. EPS for the last quarter amounts to -0.28 USD, decreased -44.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for 10X Genomics Inc (TXG)'s fundamentals?

The market is revising No Change the revenue expectations for 10x Genomics, Inc. (TXG) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 15.60%.
arrow icon

How many employees does 10X Genomics Inc (TXG). have?

10X Genomics Inc (TXG) has 1306 emplpoyees as of November 19 2025.

arrow icon

What is 10X Genomics Inc (TXG) market cap?

Today TXG has the market capitalization of 2.38B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto Tracker
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free